Company intelligence / Profile preview

Myriant

Chestertown, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Myriant uses proprietary biotechnology to produce sustainable, bio-based chemicals that displace petroleum-derived alternatives. The company manufactures bio-succinic acid and chemical intermediates that perform equal to or better than petroleum-based chemicals without requiring government subsidies.

Modalities: Fermentation-based biotechnologyBiorefinery
Industry: Non-Drug Biotech

Partnerships

PTT Chemical Group (US$60 million strategic equity investment)World-class partners and customers mentioned but not named

Beyond the preview

Go deeper on Myriant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myriant.

Explore the full profile